Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Robert K. who wrote (9119)	3/11/1999 12:43:00 PM
From: opalapril	Respond to of 17367

Ah. Thanks. Of course, you could well be right. Things are always popping in Bermuda. :=)

To: Robert K. who wrote (9119)	3/11/1999 12:48:00 PM
From: aknahow	Read Replies (1) \| Respond to of 17367

"The immediate institution of lifesaving therapeutic measures is more crucial to patient outcome than the speed and urgency with which the paediatric intensive care retrieval team arrives.9 Therefore, the resuscitation and stabilisation expertise available at the referring hospital must be harnessed while the specialist intensive care team is being mobilised." Meaningful or just common sense? Perhaps it just means the hospital team must be ready to receive the patient thats coming. Duh! Or does it mean something else? Come on Bob, those of us in the 25% crowd need help. Just tell us some of the questions you think should be asked and how you would answer them. i won't beg you. Opalapril know I don't beg.<g>

To: Robert K. who wrote (9119)	3/11/1999 1:11:00 PM
From: aknahow	Read Replies (1) \| Respond to of 17367

"There were over 2500 cases and 246 deaths in 19973 and the disease has an overall mortality of about 10%" Again a bit over 50% were just meningitis, and not related to the present trials. Question did the U.K. suddenly from 1997 to 1999 change the standard of care so much that the death rate declined greatly? No. If the overall death rate is 10% what was it for just meningococcal sepsis? Higher? In the absence of data showing how many cases and how many deaths for meningococcal sepsis I would discount any puff pieces. I think Cacaito is correct, in letting us know that this is a tough disease and carries with it a high mortality. Now with 370 patients in the trials at 20% we would have seen 74 patients no longer living if Neuprex was not working. We would have seen the trial halted for futility. And we would probably have reached the target established when the trial began with expectations of 200 enrollment. Even Bluegreen would not have dreamed up 74 non living as a reasonable target out of 200. Again, I think the market is starting to see what we have debated and have had difficulty seeing. Extension of the trial and failure to achieve a non survival rate are probably bullish events. With full confidence i predict that when the market figures out what Opalapril means we will really see what can happen. <VBG> Disregard the VBG. IMO a <g> is sufficient except for Bob.